Efficacy and safety of short‐term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open‐label, multicentre trial

Abstract

SUMMARY BackgroundThe use of tumour necrosis factor antagonists has changed the therapeutic approach to Crohn's disease.

Crohn's Disease Associated Pyoderma Gangrenosum Treated With Adalimumab

“…Adalimumab has been shown in placebo-controlled clinical trials (10) and uncontrolled studies (4,5) to be effective as induction and maintenance therapy for inflammatory bowel disease. This fully human anti-TNF-α antibody is immunogenic (5), but the role that anti-adalimumab antibodies play in the loss of response and potential hypersensitivity reactions is unknown (8).…”

“…Most common side effects include inflammation at the injection site, rash, serious infections such as septic arthritis, cellulitis, pyelonephritis, diverticulitis and opportunistic infections. Also, the possible development of autoimmune diseases and malignancies have been reported (5,10,11).…”

Adalimumab for the treatment of Crohn’s disease

“…In addition to the GAIN study, some smaller open label trials have been published confi rming the effi cacy of ADA in patients with active CD who lost responsiveness or developed intolerance to IFX (Sandborn et In the largest of these trials, Hinojosa et al (2007) analyzed the outcome of 58 patients with moderate-severe CD (36 with luminal disease and 22 with fi stulizing disease; some with both disease types), who lost response or was intolerant to IFX, receiving an induction therapy with ADA 160/80 and followed up to 52 weeks. At week 4, patients with luminal disease achieved remission in 42% and 70-point clinical response in 83%.…”

NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: a preliminary report

“…Compared to other treatments of reference such as infliximab, the subcutaneous administration of ADA offers patients an advantage by not having to depend on infusion centers. Additionally, treatment with ADA is an option on those patients who have lost response to or are intolerant to infliximab (13)(14)(15). According to clinical trials, this represents a third of the patients under infliximab during the first year of therapy (16).…”